SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
As a part of the NMD4C’s clinical research work pillar, we are supporting the development and training on validated NMD outcome measures. Considering the evolving therapeutic landscape of Spinal muscular atrophy (SMA) and the need for high-quality real-world data, convening clinicians to discuss and train on nationally agreed-upon outcome measures (OM) will enhance our capacity to uncover significant disease trajectory patterns and therapy responses.
In March, we provided an opportunity for physiotherapists and occupational therapists to attend our first training session of this kind for outcome measures in SMA.
To complement this training session, we will host an English-language training on standardizing assessment practices in SMA outcome measures later in 2024, which will include the learnings from the March training session in Quebec. We will reach out to share more information on this English-language training session when details are available.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.